Literature DB >> 17724156

An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.

Wensi S Hu1, Shu-Man Yao, Chang-Phone Fung, Yi-Ping Hsieh, Chang-Pan Liu, Jing-Fang Lin.   

Abstract

We investigated the mechanisms involved in imipenem resistance in 23 clinical strains of Acinetobacter baumannii. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed the presence of a 30-kDa protein in imipenem-intermediate A. baumannii (IIAB) and imipenem-resistant A. baumannii (IRAB) strains; this protein was almost undetectable in imipenem-susceptible A. baumannii (ISAB) strains. The 30-kDa protein was identified as an OXA-51-like carbapenemase using two-dimensional gel electrophoresis and mass spectrometry. Similar to other recent findings, bla(OXA-51-like) genes were found to exist in all 23 clinical strains; however, the transcript levels of bla(OXA-51-like) in the IIAB and IRAB were higher than in the ISAB strains using reverse transcriptase PCR (RT-PCR) and real-time RT-PCR assays. This change was due to the presence of an insertion sequence, ISAba1, upstream of bla(OXA-51-like) in the IIAB and IRAB strains that was not present in the ISAB strains. The introduction of bla(OXA-66) (a bla(OXA-51)(-like) gene), identified in ISAB ab1254 and IRAB ab1266, into Escherichia coli TOP10 cells resulted in 3.95-fold and 7.90-fold elevations in resistance to imipenem, respectively. Furthermore, when ISAB ab8 and ISAB ab1254 and their in vitro-selected imipenem-resistant mutants ISAB ab8(r) and ISAB ab1254(r) were compared, the results showed no change in the bla(OXA-66)/bla(OXA-51-like) gene sequences, in expression of the gene, and in the outer membrane protein profiles. However, there was a four- to eightfold reduction in imipenem resistance upon adding carbonyl cyanide m-chlorophenylhydrazone. Taken together, these results suggest that the OXA-66/OXA-51-like carbapenemase contributes to intrinsic resistance to imipenem; however, drug export by an efflux pump may be more important and/or occur more frequently in imipenem-resistant A. baumannii. Furthermore, this is the first report of a Taiwanese strain of an OXA-66/OXA-51-like carbapenemase that confers imipenem resistance in A. baumannii.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724156      PMCID: PMC2151406          DOI: 10.1128/AAC.01512-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  [Acinetobacter baumannii, the nosocomial pathogen par excellence].

Authors:  P Nordmann
Journal:  Pathol Biol (Paris)       Date:  2004-07

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 3.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

4.  Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa outer membrane protein.

Authors:  R B Clark
Journal:  J Antimicrob Chemother       Date:  1996-08       Impact factor: 5.790

5.  The sequences of seven class D beta-lactamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents.

Authors:  S Brown; S G B Amyes
Journal:  Clin Microbiol Infect       Date:  2005-04       Impact factor: 8.067

6.  In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.

Authors:  G A Pankuch; S A Jueneman; T A Davies; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  J Antimicrob Chemother       Date:  2004-09-08       Impact factor: 5.790

8.  Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins.

Authors:  M Gehrlein; H Leying; W Cullmann; S Wendt; W Opferkuch
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

9.  Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in trauma intensive care unit.

Authors:  S S El Shafie; M Alishaq; M Leni Garcia
Journal:  J Hosp Infect       Date:  2004-02       Impact factor: 3.926

Review 10.  Pneumonia in the intensive care unit.

Authors:  Jordi Rello; Emili Diaz
Journal:  Crit Care Med       Date:  2003-10       Impact factor: 7.598

View more
  36 in total

1.  A novel insertion sequence, ISAba10, inserted into ISAba1 adjacent to the bla(OXA-23) gene and disrupting the outer membrane protein gene carO in Acinetobacter baumannii.

Authors:  Yangsoon Lee; Chang-Ki Kim; Hyukmin Lee; Seok Hoon Jeong; Dongeun Yong; Kyungwon Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  In-silico modeling of a novel OXA-51 from β-lactam-resistant Acinetobacter baumannii and its interaction with various antibiotics.

Authors:  Vishvanath Tiwari; Isha Nagpal; Naidu Subbarao; Rajeswari R Moganty
Journal:  J Mol Model       Date:  2012-01-22       Impact factor: 1.810

3.  In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.

Authors:  Samy Figueiredo; Laurent Poirel; Jacques Croize; Christine Recule; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

4.  The structure of a doripenem-bound OXA-51 class D β-lactamase variant with enhanced carbapenemase activity.

Authors:  Cynthia M June; Taylor J Muckenthaler; Emma C Schroder; Zachary L Klamer; Zdzislaw Wawrzak; Rachel A Powers; Agnieszka Szarecka; David A Leonard
Journal:  Protein Sci       Date:  2016-09-26       Impact factor: 6.725

5.  Characterization of BRPMBL, the Bleomycin Resistance Protein Associated with the Carbapenemase NDM.

Authors:  Laurent Dortet; Delphine Girlich; Anne-Laure Virlouvet; Laurent Poirel; Patrice Nordmann; Bogdan I Iorga; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

6.  Clinical Variants of the Native Class D β-Lactamase of Acinetobacter baumannii Pose an Emerging Threat through Increased Hydrolytic Activity against Carbapenems.

Authors:  Emma C Schroder; Zachary L Klamer; Aysegul Saral; Kyle A Sugg; Cynthia M June; Troy Wymore; Agnieszka Szarecka; David A Leonard
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Multiple substitutions lead to increased loop flexibility and expanded specificity in Acinetobacter baumannii carbapenemase OXA-239.

Authors:  Thomas M Harper; Cynthia M June; Magdalena A Taracila; Robert A Bonomo; Rachel A Powers; David A Leonard
Journal:  Biochem J       Date:  2018-01-11       Impact factor: 3.857

Review 8.  Efflux-mediated antibiotic resistance in Acinetobacter spp.

Authors:  Sébastien Coyne; Patrice Courvalin; Bruno Périchon
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

9.  High prevalence of the PER-1 gene among carbapenem-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia.

Authors:  M M Aly; N M Abu Alsoud; M S Elrobh; S M Al Johani; H H Balkhy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-16       Impact factor: 3.267

10.  Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA.

Authors:  Vijaya B Srinivasan; Govindan Rajamohan; Preeti Pancholi; Kurt Stevenson; Daniel Tadesse; Prapas Patchanee; Mario Marcon; Wondwossen A Gebreyes
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-06-17       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.